Literature DB >> 6987929

Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses.

W A Briggs, R J Rozek, S D Migdal, J L Shillis, R G Brackett, F B Brandon, S K Mahajan, F D McDonald.   

Abstract

Influenza infection in renal transplant recipients may cause either morbidity and mortality or acute allograft rejection; thus, routine annual influenza vaccination should be considered. We have studied the humoral and cellular immune responses to influenza virus antigens before and after trivalent vaccine administration in 13 patients and 16 control subjects. The patients, nine of whom were either on alternate-day or low-dose daily steroid therapy, showed highly significant serum hemagglutination-inhibition antibody responses to each influenza virus strain, There was no significant change in mean lymphocyte stimulation index to any influenza virus strain after vaccination in either group. There was no correlation in the patient group between hemagglutination-inhibition antibody titer or response, or lymphocyte stimulation index or response, and the degree of allograft function or dose or duration of immunosuppressive therapy. The vigorous antibody response and the evidence of cellular immunity support the efficacy of influenza vaccination in these patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6987929     DOI: 10.7326/0003-4819-92-4-471

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  13 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 2.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.

Authors:  Ken M Kunisaki; Edward N Janoff
Journal:  Lancet Infect Dis       Date:  2009-08       Impact factor: 25.071

Review 3.  [Vaccination and multiple sclerosis].

Authors:  M Löbermann; A Winkelmann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

Review 4.  The use of vaccines in renal failure.

Authors:  D W Johnson; S J Fleming
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

5.  Effects of influenza immunization on humoral and cellular alloreactivity in humans.

Authors:  Lara Danziger-Isakov; Leonid Cherkassky; Hanni Siegel; Mary McManamon; Kristen Kramer; Marie Budev; Deirdre Sawinski; Joshua J Augustine; Donald E Hricik; Robert Fairchild; Peter S Heeger; Emilio D Poggio
Journal:  Transplantation       Date:  2010-04-15       Impact factor: 4.939

Review 6.  Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus?

Authors:  Neerja Narula; Deborah L R Yamamura; John K Marshall
Journal:  Can J Gastroenterol       Date:  2010-02       Impact factor: 3.522

7.  Seasonal maintenance of influenza vaccine-induced antibody response in kidney transplant recipients.

Authors:  Kelly A Birdwell; Mine R Ikizler; Li Wang; Daniel W Byrne; Edith C Sannella; Peter F Wright; T Alp Ikizler
Journal:  Am J Nephrol       Date:  2012-08-17       Impact factor: 3.754

Review 8.  Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols.

Authors:  Andrea Duchini; John A Goss; Saul Karpen; Paul J Pockros
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  Decreased antibody response to influenza vaccination in kidney transplant recipients: a prospective cohort study.

Authors:  Kelly A Birdwell; Mine R Ikizler; Edith C Sannella; Li Wang; Daniel W Byrne; T Alp Ikizler; Peter F Wright
Journal:  Am J Kidney Dis       Date:  2009-01-29       Impact factor: 8.860

Review 10.  Serologic vaccination response after solid organ transplantation: a systematic review.

Authors:  Isabella Eckerle; Kerstin Daniela Rosenberger; Marcel Zwahlen; Thomas Junghanss
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.